文献速递肿瘤 PET/CT核素与放射性配体治疗

晚期肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗治疗后经18F-FDG PET/CT评估达到完全代谢缓解

Complete Metabolic Response by 18 F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
PubMed 文献 · Clin Nucl Med · 2023-01-20

本文报告一例74岁晚期肝细胞癌男性患者,接受阿替利珠单抗联合贝伐珠单抗一线系统化疗后行根治性肝切除术,18F-FDG PET/CT评估显示完全代谢缓解,病理检查证实肿瘤对该治疗达到完全缓解。该病例提示18F-FDG PET/CT作为肝细胞癌免疫肿瘤药物治疗评估手段具有临床相关性。

要点

  • 74岁晚期肝细胞癌男性接受阿替利珠单抗联合贝伐珠单抗后,18F-FDG PET/CT显示完全代谢缓解。
  • 术后病理检查证实肿瘤对该联合治疗达到完全缓解。
  • 作者认为18F-FDG PET/CT是肝细胞癌免疫肿瘤药物疗效评估的有用方法。

核心结论

  • 该病例提示18F-FDG PET/CT作为肝细胞癌免疫肿瘤药物治疗评估手段具有临床相关性,是有用的方法。

研究设计与样本

  • 本文为病例报告,报告一例74岁晚期肝细胞癌男性患者。

主要发现

  • 该74岁晚期肝细胞癌男性接受阿替利珠单抗联合贝伐珠单抗治疗后,18F-FDG PET/CT评估显示完全代谢缓解。
  • 该患者随后接受根治性肝切除术,病理检查显示肿瘤对该治疗达到完全缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nowadays, atezolizumab plus bevacizumab is recommended for advanced hepatocellular carcinoma (HCC) as the first-line systemic chemotherapy. Nevertheless, the data with regard to the tumor response still remain limited. We report a complete metabolic response assessed by 18 F-FDG PET/CT in a 74-year-old man with advanced HCC who underwent atezolizumab plus bevacizumab followed by radical hepatectomy. Furthermore, pathological examination revealed that the tumor showed complete response for this therapy. This case suggests that 18 F-FDG PET/CT represents clinical relevance as a useful approach for therapeutic assessment of immune-oncology drugs in HCC.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Uchida Y, Yoh T, Fukui A, et al. Complete Metabolic Response by 18 F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Clin Nucl Med. 2023. PMID: 36727879. doi:10.1097/RLU.0000000000004570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。